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A method of quantifying centrosomes 
at the single-cell level in human normal 
and cancer tissue
ABSTRACT Centrosome abnormalities are emerging hallmarks of cancer. The overproduc-
tion of centrosomes (known as centrosome amplification) has been reported in a variety of 
cancers and is currently being explored as a promising target for therapy. However, to under-
stand different types of centrosome abnormalities and their impact on centrosome function 
during tumor progression, as well as to identify tumor subtypes that would respond to the 
targeting of a centrosome abnormality, a reliable method for accurately quantifying centro-
somes in human tissue samples is needed. Here, we established a method of quantifying 
centrosomes at a single-cell level in different types of human tissue samples. We tested mul-
tiple anti-centriole and pericentriolar-material antibodies to identify bona fide centrosomes 
and multiplexed these with cell border markers to identify individual cells within the tissue. 
High-resolution microscopy was used to generate multiple Z-section images, allowing us to 
acquire whole cell volumes in which to scan for centrosomes. The normal cells within the tis-
sue serve as internal positive controls. Our method provides a simple, accurate way to distin-
guish alterations in centrosome numbers at the level of single cells.
INTRODUCTION
The centrosome is the major microtubule-organizing center in cells 
and is crucial in defining mitotic spindle poles and forming cilia 
(Conduit et al., 2015). Centrosomes consist of pairs of centrioles that 
serve as the duplicating elements of the organelle and organize sur-
rounding layers of pericentriolar material (PCM), a protein matrix 
with microtubule-nucleating activity (Bettencourt-Dias and Glover, 
2007; Lawo et al., 2012). Cells exert tight control over centrosome 
copy number. A centrosome duplicates only once during the 
S-phase to ensure that, during mitosis, only two centrosomes are 
present to guide assembly of a bipolar spindle and enhance the 
fidelity of chromosome segregation (Nigg, 2007). Centrosome 
numerical alterations, either extra copies of centrosomes (known as 
“centrosome amplification”) or centrosome loss, can lead to chro-
mosome missegregation, resulting in the formation of micronuclei 
and aneuploid daughter cells (Khodjakov and Rieder, 2001; Ganem 
et al., 2009; Silkworth et al., 2009; Sir et al., 2013; Lambrus et al., 
2015; Wong et al., 2015). In addition, centrosome amplification pro-
motes an invasive phenotype in cultured cells and accelerates the 
rate of tumorigenesis (Godinho et al., 2014; Coelho et al., 2015; 
Sercin et al., 2016; Levine et al., 2017).
A century ago, Boveri proposed that increased numbers of cen-
trosomes and aneuploidy promote tumor formation (Boveri, 
1902/2008). At present, centrosome abnormalities, especially cen-
trosome amplification, have been reported in a variety of tumors in 
clinical samples, including both solid tumors and hematological ma-
lignancies. Indeed, centrosome abnormalities have been reported 
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to correlate with advanced tumor grade, metastasis, recurrence, 
and poor survival (Chan, 2011; Godinho and Pellman, 2014; Gonczy, 
2015). Thus, centrosome amplification is an emerging cancer hall-
mark and a prominent mechanism promoting chromosomal 
instability.
Because centrosome amplification is unique in cancer cells, 
targeting cells containing extra centrosomes may be a promising 
treatment strategy. Cells possess the robust ability to cluster super-
numerary centrosomes into a pseudobipolar spindle assembly and 
avoid multipolar division, which would be lethal (Ganem et al., 2009; 
Silkworth et al., 2009). However, such spindles frequently form incor-
rect merotelic kinetochore attachments, and the viable daughter 
cells that are produced often contain aneuploid genomes. Thus, tar-
geting the centrosome-clustering pathway offers a promising clinical 
strategy for eliminating cancer cells containing amplified centro-
somes (Leber et al., 2010; Kramer et al., 2011; Morris et al., 2017).
The compelling need for a companion assay to detect and quan-
titate centrosome abnormalities prompted the careful development 
of a reliable and accurate method for centrosome detection in hu-
man tissue specimens. The method described here would be useful 
to determine 1) inter- and intratumor heterogeneity, 2) whether dif-
ferent types of centrosome abnormalities exist in cancer (amplifica-
tion or loss), 3) whether centrosome abnormalities change with can-
cer evolution, and 4) whether different centrosome abnormalities 
predominate in specific cancer types. Previous studies identified 
centrosomes using only PCM markers, which can form assemblies 
without centrioles, and thus are not representative of centrosomes 
(Woodruff et al., 2014). An increased amount of PCM can be consid-
ered either as a centrosome structural defect (D’Assoro et al., 2002) 
or as centrosome amplification, and produces results that are diffi-
cult to quantify (Godinho and Pellman, 2014).
Here, we developed an immunofluorescence microscopy–based 
method for quantifying centrosomes at a single-cell level using dei-
dentified human Formalin-fixed paraffin-embedded (FFPE) tissue 
samples archived from a tumor bank. This method can be used to 
analyze normal biopsy specimens, surgical specimens, or tumor mi-
croarrays. Both centriole (e.g., CEP135) and PCM (e.g., γ-tubulin) 
proteins were targeted as markers to identify bona fide centro-
somes. As a proof of principle, a similar strategy has been reported 
to score centrosomes successfully in Barrett’s esophagus (BE) tissue, 
which revealed that centrosome amplification arises early in this 
cancer and its incidence is dynamic during disease progression 
(Lopes et al., 2018). In our method, E-cadherin and α6-integrin were 
used as epithelial cell border markers to identify individual cell 
boundaries and to separate epithelial cells from stroma cells. High-
resolution Z-section images were used to generate three-dimen-
sional (3D) projections of tissue regions. Thus, our method identifies 
centrosomes of whole volumes of single cells within archived human 
FFPE samples.
RESULTS AND DISCUSSION
Selection of centrosome markers
To quantify centrosome features (e.g., number or size) in individ-
ual cells, the selection of the specific structural proteins with 
which to mark these organelles is critical. The centrosome dupli-
cates in a cell cycle–dependent manner, and thus, centrosome 
copy number, structure, and the distribution of centriole and 
PCM proteins are dynamic during different cell cycle stages. De-
tailed centriole and PCM structure, as well as their assembly dur-
ing the duplication cycle, has been well-documented (Gonczy, 
2012; Brownlee and Rogers, 2013; Woodruff et al., 2014; Nigg 
and Holland, 2018).
The centrosome core contains a pair of centrioles with one fully 
matured mother centriole and a tightly associated daughter sur-
rounded by layers of PCM (Figure 1A; Nigg and Holland, 2018). 
The mature centriole has a cylindrical shape and is ∼450–500 nm in 
length with a diameter of 200–250 nm and polarized along its lon-
gitudinal axis (Gonczy, 2012; Greenan et al., 2018). We first tested 
a battery of anti-centrosomal antibodies that stain discrete foci in 
human Formalin-fixed paraffin-embedded (FFPE) tissue samples 
and identified several that met these criteria, including antibodies 
recognizing centriole proteins CEP135, CETN3, and CP110, as well 
as PCM protein γ-tubulin (Figure 1B). Images of tissue samples 
were obtained using high-resolution deconvolution microscopy 
with a resolution of ∼200 nm. CEP135 is normally restricted to the 
proximal ends of centrioles (Lin et al., 2013), and appeared as a 
single spot. In contrast, centrin and CP110 localize to the distal tip 
of centrioles (Gonczy, 2012), and typically appeared as two foci. 
Anti–γ-tubulin resulted in one focus with an irregularly shaped pat-
tern. The numbers of these foci were expected based on the distri-
bution of the proteins during the cell cycle. In the G1 phase, a cell 
normally contains one mature mother centriole connected to its 
daughter through a proximally positioned flexible linker (Figure 
1C). Thus, under these imaging conditions, a G1-phase cell nor-
mally contains two CEP135, centrin, CP110, and γ-tubulin foci 
(Figure 1D). After the G1-/S-phase transition, both centrioles dupli-
cate and spawn orthogonally positioned procentrioles closely as-
sociated with their proximal ends. Procentrioles then elongate dur-
ing the G2 phase (Figure 1C). Thus, cells in the S or G2 phase 
contain two centrosomes, each with a centriole pair and ensheathed 
in PCM. Because the distance between parent and procentriole is 
less than 200 nm, proximal-end markers of an “engaged” mother-
procentriole/daughter pair appear as a single focus, but distal-end 
markers appear as two foci per centrosome. Thus, S- and G2-phase 
cells normally contain two CEP135 foci that overlap with γ-tubulin 
and colocalize with two centrin and CP110 spots each (total of four 
centrin/CP110 foci per cell; Figure 1D). Early mitotic cells contain 
an identical pattern until mitotic exit, when mother-daughter centri-
ole pairs separate, termed “disengagement” (Tsou and Stearns, 
2006; Figure 1D).
Cancer cells with centrosome amplification deviate from these 
numbers. During mitosis, extra centrosomes cluster at spindle poles, 
with each pole containing a varied number of centriole markers and 
typically surrounded by a single PCM cloud, making accurate mea-
surement of centrosome numbers difficult. It follows that the use of 
PCM markers in mitotic cells is not a reliable method of measuring 
centrosome numbers. Thus, centrosome measurement in inter-
phase cells is the preferred method. For detection of centrosome 
amplification in mitotic cells, multiplex of centriolar and PCM mark-
ers is critical, since each spindle pole could contain more than one 
centrosome; centriolar markers would appear as multiple distinct 
spots (e.g., >2 CEP135 foci per spindle pole) with PCM surrounding 
them.
To quantify centrosome numbers per cell, we selected CEP135 
and γ-tubulin as the centrosome markers of choice, because this 
combination provides an easy-to-interpret result, since cells nor-
mally contain a constant two foci per cell throughout the cell cycle. 
More than two foci represent centrosome amplification, whereas 
less than two foci show centrosome loss. Only single uniformly 
shaped CEP135 foci that colocalized with γ-tubulin foci were scored 
as centrosomes. PCM proteins that appeared as multiple different-
sized foci that lacked centriolar markers likely represent either PCM 
fragmentation or aggregates (Pihan et al., 2001; Denu et al., 2016), 
were not considered as centrosomes by this method, and were not 
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scored. Aggregates of PCM are considered centrosomes only if they 
contain centrioles, even though they may display a microtubule-
nucleating/organizing activity. We note that centrosomal markers 
should be carefully selected in pursuing specific questions. For ex-
ample, to study PCM fragmentation or centrosome structural altera-
tions, PCM proteins coupled with proximal-end and distal-end cen-
triolar proteins are ideal. Centrosome amplification can manifest in 
different ways. For example, mother centrioles have the capacity to 
produce several daughters simultaneously, but normally do not. 
Marking both centriole proximal- and distal-end proteins can reveal 
this abnormal multiprocentriole configuration, known as a “centriole 
rosette” (Cosenza et al., 2017).
Centrosome detection at a single-cell level
To perform this procedure, FFPE tissue samples were sectioned at 
5-μm thickness and immunostained for CEP135 as a centriolar 
marker, γ-tubulin as a PCM marker, and E-cadherin or α6 integrin as 
an epithelial cell membrane marker (Figure 2A). Stained samples 
can be stored at –20°C. To quantify centrosomes, samples were first 
scanned using a low-magnification objective (e.g., 4× or 10×) to 
identify informative regions of interest (ROI). Specific ROIs were 
then imaged with a high-resolution microscope with a resolution of 
∼200 nm (e.g., confocal or deconvolution microscopy) using a high-
magnification objective (60× or 100×). Z-sections were acquired to 
obtain entire cell volumes within the ROIs. Individual cell borders 
were defined with the E-cadherin or α6 integrin label (Figure 2B). A 
3D reconstruction of the Z-section images was compiled using 
ImageJ, and specific single planes within the Z-stack were scanned 
to identify nearly every centrosome within single cells (Figure 2B).
Centriole and PCM proteins colocalize as distinct foci in 
human epithelial tissue
As a first test of our assay, we quantified centrosome numbers in 
normal human tissue. Tonsil tissue was initially used, because it is an 
industry standard for establishing a tissue-based method as it 
contains many different normal cell types. We found that CEP135 
and γ-tubulin colocalized as discrete foci (Figure 3A) and accord-
ingly scored them as centrosomes. Importantly, CEP135 appeared 
as distinct foci, whereas, in some cells, γ-tubulin foci were challeng-
ing to separate into individual foci. However, this appearance of γ-
tubulin was expected (Woodruff et al., 2014).
We next examined whether different fixation conditions could 
influence centrosome immunostaining. We used prostate cancer tis-
sues that were Formalin-fixed after being stored in frozen blocks,- 
and performed the procedure as illustrated in Figure 2B. Interest-
ingly, CEP135 appeared in different patterns: discrete bright foci as 
expected for centrosomes (Figure 3B, yellow arrowheads) and a 
roughly spherical collection of spots localized in nuclei (Figure 3B, 
FIGURE 1: The distribution and copy numbers of different centriole and PCM proteins at centrosomes vary during cell 
cycle phases. (A) Distributions of centriolar and PCM proteins at the centrosome. Scheme was adapted from Gonczy 
(2012). (B) Images show different combinations of centriole and PCM foci. Left panel: colocalization of CEP135 (red) and 
γ-tubulin (green); middle panel: colocalization of CEP135 (red) and CETN3 (green); right panel: colocalization of CP110 
(red) and γ-tubulin (green). Scale bars: 1 μm. (C) Centrosome copy number changes as the centrosome duplicates during 
the cell cycle. (D) Numbers of centriolar and PCM foci per cell during cell cycle.
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white arrowheads). On the basis of the shape and overall distribu-
tion of this latter pattern, we considered this a fixation artifact. Thus, 
different fixation conditions should be tested, because they can 
alter centrosome staining.
We next determined whether the thickness of tissue sections 
impacted the ability to quantify centrosome numbers per cell ac-
curately. Because different cell types within epithelial glands (e.g., 
basal compared with luminal epithelial cells) have different 
volumes, sectioning the tissue too thin can result in false-negative 
centrosome detection due to the loss of cell volume. Using normal 
prostate or breast tissue, sections at 4-μm thickness resulted in a 
severe loss of centrosomes; ∼60% of cells contained less than two 
centrosomes (Figure 3C). Sections at 5-μm thickness produced 
30% of cells with less than two centrosomes (Figure 3C). Sectioning 
tissue too thick could result in overlapping cell layers (Figure 4, B 
and C), making centrosome numbers difficult to quantify. For these 
reasons, the use of maximum-intensity projections to identify cen-
trosomes is not ideal. Thus, investigators should carefully test the 
appropriate tissue section thickness to avoid loss of tissue during 
sample preparation and prevent the complication of overlapping 
cells. Investigators can use normal tissue samples as controls to 
first test the maximum thickness one can use under the imaging 
conditions.
Expected outcomes from nontumor epithelial tissues
After centrosome marker selection and tissue quality evaluation, we 
next used E-cadherin and α6 integrin as epithelial cell border mark-
ers to aid in identifying centrosomes in individual cells within nontu-
mor epithelial tissues. E-cadherin was selected because it normally 
localizes to cell–cell adhesion sites known as adherens junctions in 
epithelial tissues (Gumbiner, 1996; Pecina-Slaus, 2003). However, 
advanced cancers often have abnormal E-cadherin expression with 
either loss of overall E-cadherin expression or loss of its normal lo-
calization at cell–cell adhesion (Birchmeier and Behrens, 1994; 
Thiery, 2002; Jeanes et al., 2008; Onder et al., 2008). We also tested 
α6 integrin, a laminin-binding integrin that can heterodimerize with 
β1 or β4 integrin and is normally localized at cell–ECM as well as 
cell–cell contacts (Hynes, 2002; Barczyk et al., 2010; Das et al., 
2018). Further, α6β1 integrin has been used as a biomarker of ag-
gressive tumor cells during cancer progression (Sroka et al., 2010; 
Harryman et al., 2016; Ramovs et al., 2017).
We first validated this method using normal tonsil tissue (Figure 
4A). Both stromal cells and epithelial cells contain centrosome-
marked CEP135 foci or γ-tubulin foci. E-cadherin or α6 integrin not 
only marked cell borders but also revealed the different differentia-
tion states of the stratified squamous epithelium. We next examined 
glandular epithelium samples using normal mammary-gland FFPE 
FIGURE 2: Scheme of the procedure. (A) Staining FFPE tissue. (B) Imaging acquisition and analysis.
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tissue samples (Figure 4B) and normal prostate-gland FFPE samples 
(Figure 4C). In mammary glands, both epithelium and stroma cells 
contained CEP135-labeled centrosomes. E-cadherin revealed lumi-
nal cells in the mammary gland as well as surrounding myoepithelial 
cells. In the prostate tissue sample, α6 integrin labeled the cell–cell 
and cell–ECM borders for both the basal and luminal cells within 
prostate epithelial glands. α6 integrin also recognized blood ves-
sels, which served as an internal control (Figure 4C). Specific Z-sec-
tion planes allowed detection of centrosomes in individual cells 
from overlapping cell layers that would otherwise be difficult to 
score (Figure 4, B and C, boxed right panels). In the same ROI, cen-
trosomes were detected in different Z-sections (Figure 4, B and C, 
yellow arrowheads). These results reinforce the importance of using 
Z-sections to accurately measure centrosomes in individual cells.
To evaluate the potential of high-throughput quantification of 
centrosomes with a large sample size, we tested our method using 
tissue microarrays (TMA). In the TMA we examined, the core size 
was 0.6 mm with a spacing of 0.9 mm and a total of 366 sample 
cores on each slide. TMA were immunostained for CEP135, 
γ-tubulin, and E-cadherin. Centrosomes that were labeled with both 
anti-CEP135 and γ-tubulin antibodies were detected in different 
types of normal epithelial tissue including tonsil, prostate, colon, 
and kidney (Figure 4D). In all the samples, CEP135 showed more 
quantifiable results than γ-tubulin. However, γ-tubulin staining 
contained bright and large foci compared with CEP135. Thus, an 
investment should be made to determine the most appropriate 
centrosome marker based on different tissue types and the imaging 
equipment available.
FIGURE 3: Centriole and PCM proteins colocalize at centrosomes as bright foci in human FFPE tissue. (A) A human 
normal tonsil FFPE tissue sample stained with CEP135 (red) and γ-tubulin (green). Nuclei in blue. Left panel: 
colocalization of CEP135 and γ-tubulin foci marks centrosomes in all cells. Scale bar: 100 μm. Middle panel: higher 
magnification of the boxed region in the left panel. Scale bar: 10 μm. Right panel: higher magnification of the boxed 
region in the middle panel. (B) Different staining patterns of centriolar protein CEP135 (red) in human prostate epithelial 
cancer tissue due to fixation artifact. Left panel: human prostate epithelial cancer tissue stained with E-cadherin (green), 
CEP135 (red), and DNA (blue). Right panel: CEP135 and DNA channels from the left image. Yellow arrowheads: CEP135 
foci marking centrosomes. White arrowheads: CEP135 clouds due to fixation artifact. Yellow box: CEP135 foci marking 
centrosomes at high magnification. Scale bar: 1 μm. White box: CEP135 clouds at high magnification. Scale bar: 1 μm. 
(C) Optimization of centrosome foci counting in tissue by section thickness. The centrosome foci quantitation per cell is 
expressed as a percentage of the total cells counted (percentage of cells), and the counting accuracy was tested on 
either 4- or 5-μm-thick sections from prostate or breast tissue. Error bars indicate SD. The statistical significance was 
evaluated using unpaired t tests (* indicates 0.05 > p ≥ 0.01, ns is p ≥ 0.05 for the indicated pairwise comparison).
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FIGURE 4: Expected outcomes from FFPE nontumor epithelial tissue. (A) Left panel: a normal tonsil tissue sample 
stained with E-cadherin (green), CEP135 (red), and DNA (blue). Right panel: a normal tonsil tissue sample stained with 
γ-tubulin (green), α6 integrin (red), and DNA (blue). Scale bar: 100 μm. (B) A normal mammary gland tissue sample 
stained with E-cadherin (green), CEP135 (red), and DNA (blue). Scale bar: 100 μm. Top right panel: higher magnification 
of the boxed region at a single Z-section. Bottom right panel: higher magnification of the boxed region at a different 
Z-section. Yellow arrowheads: CEP135-marked centrioles. Note that centrioles appeared at different Z-sections in cells 
within the same imaging region. Scale bar: 10 μm. (C) A normal prostate tissue sample stained with γ-tubulin (green), 
α6 integrin (red), and DNA (blue). Scale bar: 100 μm. Top right panel: higher magnification of the boxed region at a 
single Z-section. Bottom right panel: higher magnification images of the boxed region at a different Z-section. Yellow 
arrowheads indicate γ-tubulin-marked centrosomes. Scale bar: 10 μm. (D) Normal tonsil (first panel), prostate (second 
panel), colon (third panel), and kidney (far right panel) epithelial tissue from TMA stained with E-cadherin (green), 
γ-tubulin (green), CEP135 (red), and DNA (blue). Scale bar: 100 μm in the top panels and 10 μm in the bottom panels.
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Expected outcomes from cancer epithelial tissues
We next used this method on cancer tissue. We first stained for 
centrosomes and E-cadherin in high-grade (Gleason 4) prostate 
cancer tissue (Figure 5A). Interestingly, as previously reported, 
centrosome abnormalities were observed in prostate cancer 
glands (Chan, 2011). Importantly, in the same glands, we detected 
both centrosome amplification (Figure 5A, yellow arrowheads) 
and loss (Figure 5A, white arrowheads). More detailed studies 
comparing centrosome numbers in different cancers can per-
formed to determine whether similar types of centrosome abnor-
malities exist. Because advanced tumors can be associated with 
loss of E- cadherin, we next used α6 integrin as a cell border 
marker in Gleason 4 prostate cancer glands (Figure 5B) because 
α6β1 integrin is expressed in advanced cancers. We note that ag-
gressive tumors can associate with an altered α6 integrin expres-
sion pattern (Das et al., 2018). Thus, in addition to E-cadherin and 
α6 integrin, other cell border markers may be required for other 
cancer subtypes.
It would be valuable to use this method to test whether centro-
some abnormalities (amplification or loss) are associated with differ-
ent genetic instabilities and other markers associated with tumor 
aggressiveness, such as cMyc overexpression. Therefore, we multi-
plexed γ-tubulin, α6 integrin, and cMyc (Figure 5B, right panel) on 
patient tissue with Gleason Score 4 + 3 prostate cancer. In a single 
tissue section, some cells contained centrosome amplification 
(Figure 5B, right panel, yellow arrowhead), while other cancer cells 
had nuclear cMyc expression and centrosome loss. Therefore, the 
method reported here could be used in a large cohort study to 
determine whether centrosome abnormalities are associated with 
cMyc protein overexpression in the same cancer cells within the 
same tissue section. Other technologies such as fluorescence in situ 
hybridization (FISH) may also be used to test whether changes in 
centrosome numbers are associated with certain chromosomal 
abnormalities.
Because cancer cells with centrosome amplification often undergo 
centrosome clustering during mitosis, we next tested whether our 
method can detect centrosome amplification in mitotic cells. We ap-
plied our method on a triple-negative breast cancer (TNBC) tissue 
sample with detectable centrosome amplification in interphase 
cancer cells marked by CEP135 and γ-tubulin (Figure 5C, yellow 
arrowheads). Mitotic cells were identified by the presence of con-
densed chromatin (Figure 5C, white box). In the mitotic cell shown in 
Figure 5C’, one of the spindle poles contained a single centrosome, 
marked by one CEP135 and γ-tubulin colocalizing foci (upper white 
box), while the other spindle pole contained supernumerary centro-
somes marked by more than two distinct CEP135 foci with PCM 
aggregates (lower white box). Thus, centrosome amplification can be 
detected in mitotic cells exhibiting centrosome clustering using 
centriole markers.
Taking these results together, we established a method for ac-
curately quantifying bona fide centrosome numbers at the level of 
single cells in human FFPE tissue samples using markers for centri-
oles, PCM, and the cell border. Using this method, we successfully 
detected and quantified centrosomes in individual cells using 
different tissue types. The selection of centrosome and cell border 
markers can be tailored to specific biological and clinical ques-
tions. Tissue quality is important in obtaining reliable, quantifiable, 
and reproducible results. Tissue thickness should be optimized 
based on tissue type. Limitations of this method include a require-
ment for high-resolution microscopy and the need to develop 
FIGURE 5: Expected outcomes from FFPE epithelial cancer tissue. 
(A) Left panel: a Gleason grade 4 prostate cancer gland stained with 
E-cadherin (green), CEP135 (red), and DNA (blue). Scale bar: 100 μm. 
Right panel: higher magnification of the boxed region. Yellow 
arrowheads: cells with centrosome amplification. White arrowheads: 
cells with centrosome loss. Scale bar: 10 μm. (B) Left panel: a 
Gleason grade 4 gland stained with α6 integrin (red), γ-tubulin 
(green), and DNA (blue). Scale bar: 100 μm. Right panel: higher 
magnification of the boxed region stained with cMyc (red,), γ-tubulin 
(green), α6 integrin (white), and DNA (blue). Yellow arrowheads: cells 
with centrosome amplification. Scale bar: 10 μm. (C) Left panel: 
TNBC stained with E-cadherin (green), γ-tubulin (green), CEP135 
(red), and DNA (blue). Right panel: CEP135 (red) and DNA (blue) 
channels from left panel. Scale bar: 10 μm. Boxed region: a mitotic 
cell with centrosome clustering. Yellow arrowheads: cells with 
centrosome amplification. (C’) A higher magnification of the boxed 
region in C. Scale bar: 10 μm in the left panel, 1 μm in the boxed 
images.
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automated quantification. High-throughput automated quantifica-
tion is challenging due to 1) difficulties in defining ROIs because of 
different cell types in tissue, 2) difficulties in defining individual cell 
borders in 3D, and 3) differences in the size of centrosome foci, 
which can be due to the centrosome markers. Not only will studies 
of centrosome abnormalities during tumor progression benefit 
from this method, but also it could be used to screen patient sam-
ples for potentially clinically aggressive cancers.
MATERIALS AND METHODS
Reagents
Reagents used were xylene (Fisher Scientific, cat no. HC7001GAL; 
22-110-676; X16-4), 2-propanol (Fisher Scientific, cat no. A416-4), 
Antigen retrieval buffer (EnVision FLEX Target Retrieval Solution, 
high pH [50×], Dako Omnis, Code No. GV804), Tris-HCl (Sigma-
Aldrich, cat no:T5941), NaCl (Sigma-Aldrich, cat no. S9888), Tween 
20 (Sigma-Aldrich, cat no. BP337), Triton-100 (Sigma-Aldrich, cat 
no. X100), NaN3 (Fisher Scientific, cat no. S2271-25), normal goat 
serum (Sigma-Aldrich, cat no. G9023), bovine serum albumin 
(BSA) (Sigma-Aldrich, cat no. A7030), methanol (Fisher Scientific, 
cat no. A411-4), and ProLong Diamond Antifade Mountant 
(Thermo Fisher Scientific, P36970).
Antibodies
Primary antibodies are indicated in Supplemental Table 1. Second-
ary antibodies were purchased from Jackson Immunoresearch and 
used at 1:200 dilution. Hoechst 33342 (Life Technologies) was used 
at 1:1000 dilution.
Immunohistochemistry
FFPE blocks were sectioned at 5-μm thickness and mounted on 
slides. Slides were baked at 65°C overnight and deparaffined by 
washing in xylene three times, 7 min each, followed by passing 
through 100%, 75%, and 50% isopropanol and ddH2O for rehydra-
tion. Antigen retrieval was performed using EnVision FLEX target 
retrieval solution high pH (DAKO, DM828) buffer and heated at 
97°C using a decloaking chamber for 20 min. Slides were washed in 
washing buffer (0.1 M Tris-HCl, 0.3 M NaCl, 0.1% Tween 20, and 
7.7 mM NaN3, pH 7.6 at 25°C) following by blocking buffer (5% 
normal goat serum, 0.1 M Tris-HCl, and 0.15 M NaCl, pH 7.6 at 
25°C) for 30 min at room temperature. Primary antibodies were di-
luted in blocking buffer and incubated at 4°C overnight in a humidi-
fied chamber. Slides were washed three times in washing buffer and 
incubated with secondary antibody and Hoechst 33342 (1:1000; 
Invitrogen) for 30 min–1 h at room temperature. Slides were washed 
three times in washing buffer, mounted using ProLong Diamond 
Antifade Mountant (Thermo Fisher Scientific, P36970), and stored 
overnight in the dark at room temperature to cure the mountant. 
Slides were imaged as above or stored at –20°C for future analysis. 
Specimens were imaged using a DeltaVision Core system (GE 
Healthcare Bio-Sciences) equipped with an Olympus IX71 micro-
scope, a 60× objective (NA 1.42), and a cooled charge-coupled 
CoolSNAP HQ2 camera (Photometrics). Images were acquired with 
softWoRx v1.2 software (Applied Science).
Software
Software used was image acquisition software (softWoRx v1.2 
software [Applied Science]) and imaging analysis software (Adobe 
Photoshop; www.adobe.com/products/photoshopfamily.html, Im-
ageJ, or Fiji; Schindelin et al., 2012; Schneider et al., 2012).
Statistical analysis
The statistical significance of differences in average measure-
ments was evaluated using unpaired t tests (GraphPad Prism 6.0). 
Means are taken to be significantly different if p < 0.05. In figures, 
“*” indicates 0.05 > p ≥ 0.01, and not significant, “ns,” indicates 
p ≥ 0.05 for the indicated pairwise comparison. Error bars in all 
figures indicate SD.
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